Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-180: Pembrolizumab Monotherapy in Third-Line Esophageal Cancer
2015-002427-26Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in esophageal adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) and gastroesophageal junction adenocarcinoma, sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
esophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2015-002427-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002427-26.